罕见常染色体三体:无细胞DNA分析与绒毛膜绒毛样本直接染色体制备的检测比较
该研究比较了基因组宽无细胞DNA检测与绒毛膜绒毛样本直接染色体制备所检出的罕见常染色体三体谱系及临床意义。汇集10篇cfDNA报告数据,并分析TOMA实验室18年间76102例连续CVS分析。cfDNA样本中RAT阳性率0.32%,CVS滋养层样本0.41%(P<0.01);cfDNA确诊的RAT经羊膜腔穿刺确认异常的比例高于CVS滋养层(9.3% vs 3.0%,P<0.01)。作者结论:两种途径检出的RAT有很强相似性,但将CVS分析的结论应用于cfDNA检测需谨慎,反之亦然;基因组宽cfDNA检测发现的RAT对胎儿丢失、生长受限或胎儿异常的风险尚不确定。
要点
- cfDNA与CVS滋养层检出的RAT谱系有强相似性,但二者结论不可直接互推。
- cfDNA确诊RAT经羊膜腔穿刺确认异常的比例高于CVS滋养层(9.3% vs 3.0%,P<0.01)。
- cfDNA确诊RAT的151例中41.1%正常活产、27.2%胎儿丢失、7.3%表型异常、2.0%临床显著UPD、14.6%生长受限或低出生体重。
核心结论
- cfDNA分析与CVS直接染色体制备检出的RAT有很强相似性,但将CVS分析的结论应用于cfDNA检测需谨慎,反之亦然。
- 基因组宽cfDNA检测发现的RAT对胎儿丢失、生长受限或胎儿异常的风险尚不确定。
研究设计与样本
- 研究汇总10篇基因组宽cfDNA检测报告的数据,确定RAT阳性病例中最常累及的染色体并复习妊娠结局信息。
- CVS信息来自TOMA实验室18年间76102例连续CVS分析的更新数据库,分析滋养层与间充质层,RAT阳性病例建议行羊水细胞分析。
- 评估累及染色体及限制性胎盘嵌合、真性胎儿嵌合和印记染色体单亲二体(UPD),并评估流产物的RAT频率与类型。
诊断标准与关键数值
- RAT在cfDNA样本中为634/196662(0.32%),在CVS滋养层样本中为237/57539(0.41%)(P<0.01)。
- cfDNA报告间RAT频率差异超过8倍。
- 经羊膜腔穿刺确认异常的比例:cfDNA确诊RAT者14/151(9.3%)vs CVS滋养层确诊RAT者7/237(3.0%)(P<0.01)。
- cfDNA确诊的RAT中,与胎儿丢失相关的15、16、22三体比例更高。
- cfDNA确诊RAT且有结局信息的151例中:41.1%正常活产,27.2%胎儿丢失,7.3%经超声或其他随访评估发现表型异常,2.0%临床显著UPD,14.6%胎儿生长受限或低出生体重。
临床应用与阅片要点
- RAT阳性病例应结合检测途径(cfDNA或CVS)解读,cfDNA确诊者经羊膜腔穿刺确认异常的比例更高。
- cfDNA确诊RAT后需关注胎儿丢失、生长受限及表型异常等不确定风险,并按原文建议行羊水细胞分析确认。
局限性
- cfDNA报告间RAT频率差异超过8倍,提示数据存在异质性。
- 基因组宽cfDNA检测发现的RAT对胎儿丢失、生长受限或胎儿异常的风险尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Direct chromosome preparations of chorionic villus samples (CVS) and cell-free DNA (cfDNA) testing both involve analysis of the trophoblastic cell lineage. The aim of this study was to compare the spectrum of rare autosomal trisomies (RATs) detected by these two approaches and assess the available information on their clinical significance.
METHODS: Data from 10 reports on genome-wide cfDNA testing were pooled to determine which chromosomes were most frequently involved in RAT-positive cases, and pregnancy outcome information was reviewed. CVS information was obtained from an updated database of 76 102 consecutive CVS analyses performed over a period of 18 years at TOMA laboratory, in which trophoblastic and mesenchymal layers were analyzed and amniotic fluid cell analysis was recommended for RAT-positive cases. Chromosomes involved and presence of confined placental mosaicism, true fetal mosaicism and uniparental disomy (UPD) for imprinted chromosomes were assessed. Also evaluated were the frequency and types of RATs in products of conception.
RESULTS: RATs were present in 634 of 196 662 (0.32%) cfDNA samples and 237 of 57 539 (0.41%) CVS trophoblast samples (P < 0.01). The frequency of RATs varied over 8-fold between the cfDNA reports. Confirmation of abnormality through amniocentesis was more likely when RATs were ascertained through cfDNA (14 of 151; 9.3%) than through CVS trophoblasts (seven of 237; 3.0%) (P < 0.01). In cfDNA-ascertained cases, trisomies 15, 16 and 22, which are associated with fetal loss, were identified proportionately more often. Of 151 cases with RAT identified by cfDNA and outcome information available, 41.1% resulted in normal live birth; 27.2% in fetal loss; 7.3% had phenotypic abnormality detected through ultrasound or other follow-up evaluation; 2.0% had a clinically significant UPD; and 14.6% had fetal growth restriction or low birth weight. All autosomes were involved in trisomies in products of conception; the most common RATs detected were trisomies 16, 22 and 15 with a frequency of > 9% each.
CONCLUSIONS: Although there are strong parallels between RATs ascertained through cfDNA analysis and direct chromosome preparation of CVS, caution is needed in applying conclusions from CVS analysis to cfDNA testing, and vice versa. RATs identified through genome-wide cfDNA tests have uncertain risks for fetal loss, growth restriction or fetal abnormality. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Benn P, Malvestiti F, Grimi B, et al. Rare autosomal trisomies: comparison of detection through cell-free DNA analysis and direct chromosome preparation of chorionic villus samples. Ultrasound Obstet Gynecol. 2019. PMID: 31237735. doi:10.1002/uog.20383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。